239 related articles for article (PubMed ID: 22681253)
1. Biased agonism at the parathyroid hormone receptor: a demonstration of functional selectivity in bone metabolism.
Bohinc BN; Gesty-Palmer D
Mini Rev Med Chem; 2012 Aug; 12(9):856-65. PubMed ID: 22681253
[TBL] [Abstract][Full Text] [Related]
2. 'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass?
Gesty-Palmer D; Luttrell LM
Br J Pharmacol; 2011 Sep; 164(1):59-67. PubMed ID: 21506957
[TBL] [Abstract][Full Text] [Related]
3. β-arrestin-biased agonism at the parathyroid hormone receptor uncouples bone formation from bone resorption.
Bohinc BN; Gesty-Palmer D
Endocr Metab Immune Disord Drug Targets; 2011 Jun; 11(2):112-9. PubMed ID: 21476967
[TBL] [Abstract][Full Text] [Related]
4. Arrestins in bone.
Bohinc BN; Gesty-Palmer D
Prog Mol Biol Transl Sci; 2013; 118():335-58. PubMed ID: 23764060
[TBL] [Abstract][Full Text] [Related]
5. Translating in vitro ligand bias into in vivo efficacy.
Luttrell LM; Maudsley S; Gesty-Palmer D
Cell Signal; 2018 Jan; 41():46-55. PubMed ID: 28495495
[TBL] [Abstract][Full Text] [Related]
6. A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation.
Gesty-Palmer D; Flannery P; Yuan L; Corsino L; Spurney R; Lefkowitz RJ; Luttrell LM
Sci Transl Med; 2009 Oct; 1(1):1ra1. PubMed ID: 20368153
[TBL] [Abstract][Full Text] [Related]
7. Biasing the parathyroid hormone receptor: relating in vitro ligand efficacy to in vivo biological activity.
Appleton KM; Lee MH; Alele C; Alele C; Luttrell DK; Peterson YK; Morinelli TA; Luttrell LM
Methods Enzymol; 2013; 522():229-62. PubMed ID: 23374189
[TBL] [Abstract][Full Text] [Related]
8. β-Arrestin-biased signaling of PTH analogs of the type 1 parathyroid hormone receptor.
van der Lee MM; Verkaar F; Wat JW; van Offenbeek J; Timmerman M; Voorneveld L; van Lith LH; Zaman GJ
Cell Signal; 2013 Feb; 25(2):527-38. PubMed ID: 23159578
[TBL] [Abstract][Full Text] [Related]
9. β-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo.
Gesty-Palmer D; Yuan L; Martin B; Wood WH; Lee MH; Janech MG; Tsoi LC; Zheng WJ; Luttrell LM; Maudsley S
Mol Endocrinol; 2013 Feb; 27(2):296-314. PubMed ID: 23315939
[TBL] [Abstract][Full Text] [Related]
10. Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathways.
Cupp ME; Nayak SK; Adem AS; Thomsen WJ
J Pharmacol Exp Ther; 2013 Jun; 345(3):404-18. PubMed ID: 23516330
[TBL] [Abstract][Full Text] [Related]
11. Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis.
Polyzos SA; Makras P; Efstathiadou Z; Anastasilakis AD
Expert Opin Investig Drugs; 2015 Feb; 24(2):145-57. PubMed ID: 25316089
[TBL] [Abstract][Full Text] [Related]
12. Activation-independent parathyroid hormone receptor internalization is regulated by NHERF1 (EBP50).
Sneddon WB; Syme CA; Bisello A; Magyar CE; Rochdi MD; Parent JL; Weinman EJ; Abou-Samra AB; Friedman PA
J Biol Chem; 2003 Oct; 278(44):43787-96. PubMed ID: 12920119
[TBL] [Abstract][Full Text] [Related]
13. Refining efficacy: exploiting functional selectivity for drug discovery.
Gesty-Palmer D; Luttrell LM
Adv Pharmacol; 2011; 62():79-107. PubMed ID: 21907907
[TBL] [Abstract][Full Text] [Related]
14. Retromer in Osteoblasts Interacts With Protein Phosphatase 1 Regulator Subunit 14C, Terminates Parathyroid Hormone's Signaling, and Promotes Its Catabolic Response.
Xiong L; Xia WF; Tang FL; Pan JX; Mei L; Xiong WC
EBioMedicine; 2016 Jul; 9():45-60. PubMed ID: 27333042
[TBL] [Abstract][Full Text] [Related]
15. Delineation of a conserved arrestin-biased signaling repertoire in vivo.
Maudsley S; Martin B; Gesty-Palmer D; Cheung H; Johnson C; Patel S; Becker KG; Wood WH; Zhang Y; Lehrmann E; Luttrell LM
Mol Pharmacol; 2015 Apr; 87(4):706-17. PubMed ID: 25637603
[TBL] [Abstract][Full Text] [Related]
16. Loss of Gsα in the Postnatal Skeleton Leads to Low Bone Mass and a Blunted Response to Anabolic Parathyroid Hormone Therapy.
Sinha P; Aarnisalo P; Chubb R; Poulton IJ; Guo J; Nachtrab G; Kimura T; Swami S; Saeed H; Chen M; Weinstein LS; Schipani E; Sims NA; Kronenberg HM; Wu JY
J Biol Chem; 2016 Jan; 291(4):1631-1642. PubMed ID: 26598522
[TBL] [Abstract][Full Text] [Related]
17. Beta-arrestin-biased parathyroid hormone ligands: a new approach to the development of agents that stimulate bone formation.
Ferrari SL; Bouxsein ML
Sci Transl Med; 2009 Oct; 1(1):1ps1. PubMed ID: 20368152
[TBL] [Abstract][Full Text] [Related]
18. Endogenous parathyroid hormone-related protein compensates for the absence of parathyroid hormone in promoting bone accrual in vivo in a model of bone marrow ablation.
Zhu Q; Zhou X; Zhu M; Wang Q; Goltzman D; Karaplis A; Miao D
J Bone Miner Res; 2013 Sep; 28(9):1898-911. PubMed ID: 23716486
[TBL] [Abstract][Full Text] [Related]
19. One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption.
Varela A; Chouinard L; Lesage E; Smith SY; Hattersley G
J Bone Miner Res; 2017 Jan; 32(1):24-33. PubMed ID: 27748532
[TBL] [Abstract][Full Text] [Related]
20. Extracellular nucleotides enhance agonist potency at the parathyroid hormone 1 receptor.
Kim BH; Pereverzev A; Zhu S; Tong AOM; Dixon SJ; Chidiac P
Cell Signal; 2018 Jun; 46():103-112. PubMed ID: 29501726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]